Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LOS ANGELES--(BUSINESS WIRE)--MOONLAKE IMMUNOTHERAPEUTICS SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  MLTX.

MOONLAKE IMMUNOTHERAPEUTICS SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  MLTX

BRAGAR EAGEL & SQUIRE, P.C. LITIGATION PARTNER BRANDON WALKER ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN MOONLAKE (MLTX) TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

MOONLAKE DECEMBER 15TH DEADLINE: BRAGAR EAGEL & SQUIRE, P.C. URGENTLY REMINDS MOONLAKE IMMUNOTHERAPEUTICS INVESTORS TO CONTACT THE FIRM

NEW YORK--(BUSINESS WIRE)---- $MLTX #CLASSACTION--FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST REUTERS RESEARCH INC. (MOONLAKE OR THE COMPANY) (NASDAQ: MLTX) AND REMINDS INVESTORS OF THE DECEMBER 15, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. FARUQI & FARUQI IS A LEADING NATIONAL SECURITIES LAW FIRM WITH OFFICES IN NEW YORK, PENNSYLVANIA, CALIFORNIA AND GEORGIA. TH.

FINAL DEADLINE ALERT: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF MOONLAKE IMMUNOTHERAPEUTICS

LOS ANGELES , DEC. 15, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS ("MOONLAKE " OR "THE COMPANY") (NASDAQ: MLTX ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF MLTX DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

MOONLAKE IMMUNOTHERAPEUTICS SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS - MLTX

NEW YORK, DEC. 12, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN MOONLAKE IMMUNOTHERAPEUTICS ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) OF A CLASS ACTION SECURITIES LAWSUIT.

MOONLAKE IMMUNOTHERAPEUTICS SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT LEVI & KORSINSKY FOR MORE INFORMATION  MLTX

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN MOONLAKE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

INVESTOR DEADLINE APPROACHING: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF MOONLAKE IMMUNOTHERAPEUTICS

PHILADELPHIA , DEC. 11, 2025 /PRNEWSWIRE/ --NATIONAL PLAINTIFFS' LAW FIRM BERGER MONTAGUE PC ANNOUNCES A CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) ("MOONLAKE" OR THE "COMPANY") ON BEHALF OF INVESTORS WHO PURCHASED MOONLAKE SHARES DURING THE PERIOD OF MARCH 10, 2024 THROUGH SEPTEMBER 29, 2025 (THE "CLASS PERIOD"). INVESTOR DEADLINE: INVESTORS WHO PURCHASED MOONLAKESECURITIES DURING THE CLASS PERIOD MAY, NO LATER THAN DECEMBER 15, 2025 , SEEK TO BE APPOINTED AS A LEAD PLAINTIFF REPRESENTATIVE OF THE CLASS.

DEADLINE NEXT WEEK: BERGER MONTAGUE ADVISES MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) INVESTORS TO CONTACT THE FIRM BEFORE DECEMBER 15, 2025

LOS ANGELES , DEC. 11, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS ("MOONLAKE " OR "THE COMPANY") (NASDAQ: MLTX ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF MLTX DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

NEW YORK , DEC. 9, 2025 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN MOONLAKE IMMUNOTHERAPEUTICS ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) OF A CLASS ACTION SECURITIES LAWSUIT. CLASS DEFINITION: THE LAWSUIT SEEKS TO RECOVER LOSSES ON BEHALF OF MOONLAKE INVESTORS WHO WERE ADVERSELY AFFECTED BY ALLEGED SECURITIES FRAUD BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025.

INVESTORS IN MOONLAKE IMMUNOTHERAPEUTICS SHOULD CONTACT LEVI & KORSINSKY BEFORE DECEMBER 15, 2025 TO DISCUSS YOUR RIGHTS - MLTX

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN MOONLAKE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN MOONLAKE BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 8, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST MOONLAKE IMMUNOTHERAPEUTICS ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) AND REMINDS INVESTORS OF THE DECEMBER 15, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

MLTX INVESTOR NOTICE: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF MOONLAKE IMMUNOTHERAPEUTICS

LOS ANGELES , DEC. 8, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS ("MOONLAKE " OR "THE COMPANY") (NASDAQ: MLTX ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF MLTX DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN MOONLAKE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN MOONLAKE BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , DEC. 5, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST REUTERS RESEARCH INC. ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) AND REMINDS INVESTORS OF THE DECEMBER 15, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

SHAREHOLDER ACTION REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF MOONLAKE IMMUNOTHERAPEUTICS

NEW YORK, DEC. 05, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A LAWSUIT HAS BEEN FILED AGAINST MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN MOONLAKE, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/MOONLAKE-IMMUNOTHERAPEUTICS-CLASS-ACTION-LAWSUIT.

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) INVESTORS ARE ENCOURAGED TO ACT BEFORE THE UPCOMING DECEMBER 15 SECURITIES FRAUD DEADLINE  CONTACT BFA LAW IF YOU LOST MONEY

LOS ANGELES, DEC. 05, 2025 (GLOBE NEWSWIRE) -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS (MOONLAKE OR THE COMPANY) (NASDAQ: MLTX) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF MLTX DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

MLTX INVESTOR WITH LOSSES ENCOURAGES TO CONTACT FIRM BY DEC. 15 DEADLINE SAN FRANCISCO , DEC. 5, 2025 /PRNEWSWIRE/ -- GLOBAL PLAINTIFFS' RIGHTS LAW FIRM HAGENS BERMAN REMINDS INVESTORS THAT THE DEADLINE TO MOVE THE COURT FOR APPOINTMENT AS LEAD PLAINTIFF IN THE SECURITIES CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS, INC. (NASDAQ: MLTX) IS DECEMBER 15, 2025 . "IN SPECIALIZED BIOTECH CASES, THE CORE LEGAL QUESTION IS OFTEN WHETHER THE COMPANY'S CLAIMS ABOUT THE STUDY MATCH THE REALITY OF THE CLINICAL DATA IT WAS RECEIVING," SAID REED KATHREIN , THE HAGENS BERMAN PARTNER LEADING THE LITIGATION.

MOONLAKE'S (MLTX) SLK EFFICACY CLAIMS UNDER SCRUTINY AFTER 90% PLUNGE; FOCUS ON NANOBODY VS. BIMZELX SUPERIORITY- HAGENS BERMAN

LOS ANGELES , DEC. 4, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS ("MOONLAKE " OR "THE COMPANY") (NASDAQ: MLTX ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF MLTX DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

NEW YORK, DEC. 03, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFMOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX).

MOONLAKE IMMUNOTHERAPEUTICS SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT THE GROSS LAW FIRM FOR MORE INFORMATION  MLTX

MLTX INVESTOR WITH LOSSES ENCOURAGES TO CONTACT FIRM BY DEC. 15 DEADLINE SAN FRANCISCO , DEC. 3, 2025 /PRNEWSWIRE/ -- GLOBAL PLAINTIFFS' RIGHTS LAW FIRM HAGENS BERMAN REMINDS INVESTORS THAT THE DEADLINE TO MOVE THE COURT FOR APPOINTMENT AS LEAD PLAINTIFF IN THE SECURITIES CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS, INC. (NASDAQ: MLTX) IS DECEMBER 15, 2025 . "IN SPECIALIZED BIOTECH CASES, THE CORE LEGAL QUESTION IS OFTEN WHETHER THE COMPANY'S CLAIMS ABOUT THE STUDY MATCH THE REALITY OF THE CLINICAL DATA IT WAS RECEIVING," SAID REED KATHREIN , THE HAGENS BERMAN PARTNER LEADING THE LITIGATION.

MOONLAKE IMMUNOTHERAPEUTICS INVESTORS THAT LOST MONEY ARE NOTIFIED TO CONTACT BFA BEFORE THE DECEMBER 15, 2025 SECURITIES FRAUD CLASS ACTION DEADLINE.

MLTX NEWS: MOONLAKE IMMUNOTHERAPEUTICS SUED FOR SECURITIES FRAUD AFTER STOCK PLUMMETS 90% -- INVESTORS NOTIFIED TO CONTACT BFA LAW BY DECEMBER 15 DEADLINE

NEW YORK, DEC. 02, 2025 (GLOBE NEWSWIRE) -- BRAGAR EAGEL & SQUIRE, P.C., A NATIONALLY RECOGNIZED SHAREHOLDER RIGHTS LAW FIRM, REMINDS INVESTORS THAT CLASS ACTIONS HAVE BEEN COMMENCED ON BEHALF OF STOCKHOLDERS OF CEPTON, INC. (NASDAQ:CPTN) AND MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX). STOCKHOLDERS HAVE UNTIL THE DEADLINES BELOW TO PETITION THE COURT TO SERVE AS LEAD PLAINTIFF. ADDITIONAL INFORMATION ABOUT EACH CASE CAN BE FOUND AT THE LINK PROVIDED.

BRAGAR EAGEL & SQUIRE, P.C. URGES INVESTORS OF CEPTON, AND MOONLAKE TO INQUIRE ABOUT THEIR RIGHTS BEFORE UPCOMING DEADLINES

NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 2, 2025) - LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A LAWSUIT HAS BEEN FILED AGAINST MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN MOONLAKE, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/MOONLAKE-IMMUNOTHERAPEUTICS-CLASS-ACTION-LAWSUIT.

MLTX COURT ALERT: MOONLAKE IMMUNOTHERAPEUTICS INVESTORS ARE NOTIFIED THE COMPAY HAS BEEN SUED FOR SECURITIES FRAUD AND ARE NOTIFIED TO CONTACT BFA LAW BY DECEMBER 15

NEW YORK , DEC. 2, 2025 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN MOONLAKE IMMUNOTHERAPEUTICS ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) OF A CLASS ACTION SECURITIES LAWSUIT. CLASS DEFINITION: THE LAWSUIT SEEKS TO RECOVER LOSSES ON BEHALF OF MOONLAKE INVESTORS WHO WERE ADVERSELY AFFECTED BY ALLEGED SECURITIES FRAUD BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025.

MOONLAKE IMMUNOTHERAPEUTICS SUED FOR SECURITIES LAW VIOLATIONS - CONTACT LEVI & KORSINSKY BEFORE DECEMBER 15, 2025 TO DISCUSS YOUR RIGHTS - MLTX

LOS ANGELES, DEC. 02, 2025 (GLOBE NEWSWIRE) -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS (MOONLAKE OR THE COMPANY) (NASDAQ: MLTX) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF MLTX DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN MOONLAKE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN MOONLAKE BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 1, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST REUTERS RESEARCH INC. ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) AND REMINDS INVESTORS OF THE DECEMBER 15, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

UPCOMING DEADLINE: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF MOONLAKE IMMUNOTHERAPEUTICS

NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 1, 2025) - LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A LAWSUIT HAS BEEN FILED AGAINST MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN MOONLAKE, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/MOONLAKE-IMMUNOTHERAPEUTICS-CLASS-ACTION-LAWSUIT.

MLTX SHAREHOLDERS: MOONLAKE IMMUNOTHERAPEUTICS INVESTORS WITH LOSSES MAY HAVE BEEN MISLED BY THE COMPANY AND ARE URGED TO CONTACT BFA LAW BY DECEMBER 15

LOSANGELES, DEC. 1, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS ("MOONLAKE " OR "THE COMPANY") (NASDAQ: MLTX ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF MLTX DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN MOONLAKE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN MOONLAKE BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - NOVEMBER 28, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST REUTERS RESEARCH INC. ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) AND REMINDS INVESTORS OF THE DECEMBER 15, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

LOS ANGELES, NOV. 28, 2025 (GLOBE NEWSWIRE) -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS (MOONLAKE OR THE COMPANY) (NASDAQ: MLTX) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF MLTX DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

MLTX INVESTORS WITH LOSSES ENCOURAGED TO CONTACT THE FIRM SAN FRANCISCO, CALIFORNIA--(NEWSFILE CORP. - NOVEMBER 27, 2025) - MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY, HAS BEEN HIT WITH A SECURITIES FRAUD CLASS ACTION LAWSUIT AFTER ITS SHARE PRICE PLUMMETED NEARLY 90% IN A SINGLE DAY. THE SHARP DECLINE WAS TRIGGERED BY THE RELEASE OF DISAPPOINTING PHASE 3 TRIAL RESULTS FOR ITS LEAD AND ONLY DRUG CANDIDATE, SONELOKIMAB (SLK).

MOONLAKE IMMUNOTHERAPEUTICS' (MLTX) REPORTED PHASE 3 TRIAL DATA FOR SOLE DRUG CANDIDATE, 90% STOCK CRASH TRIGGERS INVESTOR SUIT -- HAGENS BERMAN

MLTX INVESTORS WITH LOSSES ENCOURAGED TO CONTACT HAGENS BERMAN SAN FRANCISCO , NOV. 25, 2025 /PRNEWSWIRE/ --MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY, HAS BEEN HIT WITH A SECURITIES FRAUD CLASS ACTION LAWSUIT AFTER ITS SHARE PRICE PLUMMETED NEARLY 90% IN A SINGLE DAY. THE SHARP DECLINE WAS TRIGGERED BY THE RELEASE OF DISAPPOINTING PHASE 3 TRIAL RESULTS FOR ITS LEAD AND ONLY DRUG CANDIDATE, SONELOKIMAB (SLK).

LOS ANGELES, NOV. 25, 2025 (GLOBE NEWSWIRE) -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS (MOONLAKE OR THE COMPANY) (NASDAQ: MLTX) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF MLTX DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

SAN FRANCISCO, NOV. 24, 2025 (GLOBE NEWSWIRE) -- MOONLAKE IMMUNOTHERAPEUTICS(NASDAQ: MLTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY, HAS BEEN HIT WITH A SECURITIES FRAUD CLASS ACTION LAWSUIT AFTER ITS SHARE PRICE PLUMMETED NEARLY 90% IN A SINGLE DAY. THE SHARP DECLINE WAS TRIGGERED BY THE RELEASE OF DISAPPOINTING PHASE 3 TRIAL RESULTS FOR ITS LEAD AND ONLY DRUG CANDIDATE, SONELOKIMAB (SLK).

NEW YORK, NOV. 24, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFMOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX).

INVESTORS IN MOONLAKE IMMUNOTHERAPEUTICS SHOULD CONTACT THE GROSS LAW FIRM BEFORE DECEMBER 15, 2025 TO DISCUSS YOUR RIGHTS  MLTX

NEW YORK , NOV. 24, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX). SHAREHOLDERS WHO PURCHASED SHARES OF MLTX DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT.

MOONLAKE IMMUNOTHERAPEUTICS SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE GROSS LAW FIRM BEFORE DECEMBER 15, 2025 TO DISCUSS YOUR RIGHTS - MLTX

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN MOONLAKE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN MOONLAKE BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - NOVEMBER 24, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST REUTERS RESEARCH INC. ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) AND REMINDS INVESTORS OF THE DECEMBER 15, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

NEW YORK, NEW YORK--(NEWSFILE CORP. - NOVEMBER 24, 2025) - LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A LAWSUIT HAS BEEN FILED AGAINST MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN MOONLAKE, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/MOONLAKE-IMMUNOTHERAPEUTICS-CLASS-ACTION-LAWSUIT.

MOONLAKE NOTICE: MOONLAKE IMMUNOTHERAPEUTICS (MLTX) FACES SECURITIES FRAUD ALLEGATIONS AFTER STOCK DROPS 90%, INVESTORS URGED TO CONTACT BFA LAW

MLTX COURT ALERT: MOONLAKE IMMUNOTHERAPEUTICS INVESTORS THAT LOST MONEY MAY HAVE BEEN AFFECTED BY FRAUD -- CONTACT BFA LAW BY DECEMBER 15

SAN FRANCISCO, NOV. 21, 2025 (GLOBE NEWSWIRE) -- MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY, HAS BEEN HIT WITH A SECURITIES FRAUD CLASS ACTION LAWSUIT AFTER ITS SHARE PRICE PLUMMETED NEARLY 90% IN A SINGLE DAY. THE SHARP DECLINE WAS TRIGGERED BY THE RELEASE OF DISAPPOINTING PHASE 3 TRIAL RESULTS FOR ITS LEAD AND ONLY DRUG CANDIDATE, SONELOKIMAB (SLK).

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN MOONLAKE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN MOONLAKE BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , NOV. 21, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST REUTERS RESEARCH INC. ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) AND REMINDS INVESTORS OF THE DECEMBER 15, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

NEW YORK , NOV. 21, 2025 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN MOONLAKE IMMUNOTHERAPEUTICS ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) OF A CLASS ACTION SECURITIES LAWSUIT. CLASS DEFINITION: THE LAWSUIT SEEKS TO RECOVER LOSSES ON BEHALF OF MOONLAKE INVESTORS WHO WERE ADVERSELY AFFECTED BY ALLEGED SECURITIES FRAUD BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025.

MOONLAKE IMMUNOTHERAPEUTICS SUED FOR SECURITIES LAW VIOLATIONS - INVESTORS SHOULD CONTACT LEVI & KORSINSKY FOR MORE INFORMATION - MLTX

LOS ANGELES , NOV. 21, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS ("MOONLAKE " OR "THE COMPANY") (NASDAQ: MLTX ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF MLTX DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN MOONLAKE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN MOONLAKE BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - NOVEMBER 18, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST REUTERS RESEARCH INC. ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) AND REMINDS INVESTORS OF THE DECEMBER 15, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

NEW YORK , NOV. 18, 2025 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN MOONLAKE IMMUNOTHERAPEUTICS ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) OF A CLASS ACTION SECURITIES LAWSUIT. CLASS DEFINITION: THE LAWSUIT SEEKS TO RECOVER LOSSES ON BEHALF OF MOONLAKE INVESTORS WHO WERE ADVERSELY AFFECTED BY ALLEGED SECURITIES FRAUD BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025.

LOS ANGELES, NOV. 18, 2025 (GLOBE NEWSWIRE) -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST MOONLAKE IMMUNOTHERAPEUTICS (MOONLAKE OR THE COMPANY) (NASDAQ: MLTX) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF MLTX DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN MOONLAKE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN MOONLAKE BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - NOVEMBER 17, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST REUTERS RESEARCH INC. ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) AND REMINDS INVESTORS OF THE DECEMBER 15, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

NEW YORK , NOV. 17, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFMOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX). SHAREHOLDERS WHO PURCHASED SHARES OF MLTX DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT.

NEW YORK , NOV. 14, 2025 /PRNEWSWIRE/ -- LEVI &KORSINSKY, LLP NOTIFIES INVESTORS IN MOONLAKE IMMUNOTHERAPEUTICS ("MOONLAKE" OR THE "COMPANY") (NASDAQ: MLTX) OF A CLASS ACTION SECURITIES LAWSUIT. CLASS DEFINITION: THE LAWSUIT SEEKS TO RECOVER LOSSES ON BEHALF OF MOONLAKE INVESTORS WHO WERE ADVERSELY AFFECTED BY ALLEGED SECURITIES FRAUD BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025.

NEW YORK, NEW YORK--(NEWSFILE CORP. - NOVEMBER 14, 2025) - LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A LAWSUIT HAS BEEN FILED AGAINST MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN MOONLAKE, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/MOONLAKE-IMMUNOTHERAPEUTICS-CLASS-ACTION-LAWSUIT.

MoonLake Immunotherapeutics

MLTX

Price

Financial Reports

No items found.

Press Releases

MoonLake Immunotherapeutics

MLTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

MLTX